ALM27134 / Glenmark, Almirall - LARVOL DELTA

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline (Businesswire) - "After the approval of Ebglyss (lebrikizumab) by the European Commission (EC)...the product has now launched in 11 countries in Europe...and in 2025: Italy, Switzerland, Austria, Belgium, and Sweden). The rollout in the remaining European countries is expected throughout 2025....Sarecycline’s (Seysara) regulatory review in China is ongoing with an anticipated approval in the second half of 2025. To expand the label for Klisyri to include large field application also in Europe, a current clinical study is aimed at enabling approval for an anticipated launch in 2026....Sun Pharma is running two Phase III studies to assess the efficacy and safety of tildrakizumab in patients suffering from psoriatic arthritis. First results are expected in the second half of 2025....The company is continuing to advance the asset ALM27134...The start of a Phase II study is planned for later this year in patients suffering from Hidradenitis Suppurativa."

China approval • Launch Europe • New P2 trial • P3 data • Dermatology • Hidradenitis Suppurativa • Psoriatic Arthritis